Meeting Banner
Abstract #3066

Identifying Rapamycin as a potential preventative therapeutic for Alzheimer’s disease through Multimodal MRl

Mengfan Xia1 and Ai-Ling Lin1,2

1Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY, United States, 2Sanders Brown Center on Aging, University of Kentucky, Lexington, KY, United States

The ε4 allele of apolipoprotein E gene (APOE4) is the strongest genetic risk factor for Alzheimer’s disease (AD). Studies have indicated that APOE4 carriers develop vascular and metabolic dysfunctions several decades prior to the clinical symptom of dementia occurs. In this study, we used multi-modal MRI markers to investigate the effect of Rapamycin, a FDA approved drug, on genetically modified pre-symptomatic E4FAD mice, as a preventative therapeutic for AD. Cerebral blood flow and crucial brain metabolites detected by MR spectroscopy were restored in Rapamycin fed mice, consistent with lower BOLD responses, lower cerebrovascular-reactivity (CVR) and decreased Amyloid-beta deposition.

This abstract and the presentation materials are available to members only; a login is required.

Join Here